Shionogi Company Analysis

  • ID: 4421390
  • Company Profile
  • 35 pages
  • Datamonitor Healthcare
  • Shionogi and Co ltd
1 of 3
Updated analysis and forecasts based on 2016 company-reported sales.

Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.

  • 2021 outlook - Shionogi will add over $300m in revenue out to 2021 as it expands its market share in HIV.
  • 2026 outlook - The company will experience minimal growth out to 2026 as mid-term growth is offset by patent expiries.
  • Events - The expansion of the HIV franchise and CNS portfolio will offset the continued erosion of Crestor.
  • Shionogi’s prescription pharmaceutical sales are forecast to achieve modest growth.
  • Shionogi’s CNS portfolio will be a major contributor to sales growth.
  • New products Tivicay and Triumeq will be the key driver for Shionogi.
Model updates
  • Symproic launch in the US and Japan
  • Analysis structure
Company context
  • How is Shionogi strategically poised out to 2026?
  • What are Shionogi’s key strengths, weaknesses, opportunities, and threats?
  • What are Shionogi’s key catalysts over the next four quarters?
Facts and figures
  • What is Shionogi’s forecasted sales performance out to 2026?
  • What is the revenue trajectory of Shionogi’s current top 10 products out to 2026?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Shionogi based on the lifecycle of products?
Key therapy areas
  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Shionogi’s important therapeutic markets?
  • How is Shionogi adapting strategically to internal and external headwinds?
Note: Product cover images may vary from those shown
2 of 3
  • Crestor cliff
  • Shionogi growth strategy
  • Licensing efforts
  • Outlook
  • Shionogi’s SWOT analysis
  • Shionogi’s key events and catalysts
  • Shionogi’s prescription pharma sales outlook
  • Shionogi’s therapy area dynamics
  • Shionogi’s top 10 products over 2016-26
  • Shionogi’s launch/core/expiry analysis
  • Shionogi’s financial outlook
  • Shionogi’s M&A history
  • Metabolic
  • Central nervous system
  • Infectious diseases
  • Genitourinary

List of Figures
Figure 1: Shionogi’s prescription pharmaceutical sales ($m) and growth rate (%), 2013-26
Figure 2: Shionogi’s therapy area dynamics, 2016-26
Figure 3: Shionogi’s top 10 product sales ($m), 2016-26
Figure 4: Shionogi’s launch/core/expiry analysis, 2016-26
Figure 5: Shionogi’s operating revenue/cost analysis ($m), 2010-22

List of Tables
Table 1: Shionogi’s sales by therapy area ($m), 2016-26
Table 2: Shionogi’s growth drivers and resistors
Table 3: Shionogi’s sales by launch, core, and expiry portfolio ($m), 2016-26
Table 4: Shionogi’s financial performance, 2015-22
Table 5: Shionogi’s key merger and acquisition deals, 2003-16
Table 6: Shionogi’s metabolic portfolio ($m), 2016-26
Table 7: Shionogi’s central nervous system portfolio ($m), 2016-26
Table 8: Shionogi’s infectious diseases portfolio ($m), 2016-26
Table 9: Shionogi’s genitourinary portfolio ($m), 2016-26
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown